Subacute combined degeneration of the spinal cord (SACD) is the most severe neurological complication of B12 deficiency and the one where the speed of diagnosis determines the outcome — the pathology is demyelination of: (1) the posterior columns (dorsal columns — responsible for vibration, proprioception, and joint position sense), causing sensory ataxia, positive Romberg test, and falls; and (2) the corticospinal tracts (lateral columns), causing progressive spastic paraparesis with upper motor neurone signs (hyper-reflexia, Babinski positive, clonus). The critical clinical principle: SACD can occur WITHOUT macrocytic anaemia — neurological manifestations of B12 deficiency can precede or occur entirely independently of haematological changes. This means that a patient with a normal full blood count, and even a normal-range serum B12 (if borderline), can still be developing SACD. The MRI spine shows characteristic T2 hyperintensity in the posterior and lateral columns. Nitrous oxide (laughing gas) abuse is an increasingly common cause of acute SACD in young people — N2O irreversibly oxidises the cobalt in cobalamin from the Co+ active form to the inactive Co3+ form, causing acute functional B12 deficiency that can cause SACD within days to weeks of heavy use. Serum B12 levels may be misleadingly normal — homocysteine and methylmalonic acid are the sensitive functional markers.

Pernicious anaemia is the most important cause of B12 deficiency in UK primary care — it is an autoimmune condition in which antibodies destroy gastric parietal cells (anti-parietal cell antibodies, APC-Ab, present in approximately 90% of PA patients) and/or block intrinsic factor synthesis or B12-IF binding (anti-intrinsic factor antibodies, IF-Ab, present in approximately 50% of PA patients). The condition disproportionately affects: women (2:1 female:male ratio), Northern European populations (particularly Scandinavian), elderly patients (peak incidence in the 6th-7th decade), and patients with other autoimmune conditions (thyroid disease, vitiligo, Addison's disease, type 1 diabetes — polyglandular autoimmune syndrome). The lifelong requirement for B12 injections is the most important management principle — PA patients who stop their B12 injections will develop deficiency again within months because the underlying absorption defect is permanent. GPs who conduct annual medication reviews and consider stopping 'unnecessary' B12 injections in PA patients are at risk of causing iatrogenic SACD. The injection should never be stopped once diagnosed in PA.

The borderline serum B12 grey zone (180-300 ng/L) is one of the most clinically challenging areas in routine blood test interpretation — approximately 50% of patients with serum B12 in this range have functional intracellular B12 deficiency (demonstrable by elevated homocysteine and/or MMA), while the other 50% have adequate B12 stores. The practical approach for primary care: (1) treat the clinical picture — if the patient has symptoms consistent with B12 deficiency (fatigue, peripheral neuropathy, cognitive change) with borderline B12, treat empirically with IM hydroxocobalamin; (2) arrange functional markers (MMA + homocysteine) if available — elevated levels in a borderline-B12 patient confirm functional deficiency; (3) check folate — isolated folate deficiency also causes elevated homocysteine; (4) the reticulocyte response to the first B12 injection is a useful diagnostic test — a peak reticulocyte count at days 5-7 post-injection confirms that the anaemia was indeed B12-responsive. The maxim in UK practice: 'If in doubt, treat — the treatment is safe and inexpensive.'

The gastric carcinoid risk in pernicious anaemia is clinically important but often omitted from patient education at diagnosis — PA causes chronic achlorhydria (absence of gastric acid due to parietal cell destruction). The loss of acid causes: (1) reflex hypergastrinaemia (antral G cells secrete gastrin attempting to stimulate acid production from the absent parietal cells); (2) sustained hypergastrinaemia is a trophic stimulus for enterochromaffin-like (ECL) cells in the gastric fundus, leading over many years to ECL cell hyperplasia and eventually type I gastric carcinoid tumours. Type I gastric carcinoids are the most benign of the three gastric carcinoid types — they are almost exclusively associated with hypergastrinaemia from PA (or autoimmune atrophic gastritis), are usually small (<1 cm), multiple, and have an extremely low risk of metastasis (<5%). They can be monitored with 5-yearly gastroscopy and treated by endoscopic resection if they grow. Patients should be reassured: this is not the aggressive gastric cancer that most people fear, and regular surveillance ensures they are identified and managed appropriately.

The single gastroscopy at PA diagnosis is a NICE-recommended quality standard — it serves two purposes: exclusion of gastric malignancy (atrophic gastritis from PA carries approximately 1-3% lifetime gastric cancer risk — significantly higher than the general population but still modest) and exclusion of type I gastric carcinoid. The practical issue is that many PA patients diagnosed in primary care never receive this gastroscopy because the GP either does not know about the recommendation or does not refer. GPs diagnosing PA (positive IF-Ab + B12 deficiency, or clinical diagnosis with APC-Ab + low B12 + appropriate clinical picture) should add an endoscopy referral as part of the initial management plan. The patient does not need to be symptomatic for the endoscopy — it is surveillance, not diagnostic, in the majority of cases.

The debate about injection frequency in pernicious anaemia is one of the most contested areas in UK primary care — the NHS protocol (1 mg IM hydroxocobalamin every 3 months) is based on pharmacokinetic data showing that the body can store 2-5 mg of B12, that a 1 mg injection repletes stores, and that stores last approximately 3 months in a healthy person. However, many PA patients and patient advocacy groups (Pernicious Anaemia Society) argue that individual variation in B12 metabolism means that some patients experience return of symptoms (fatigue, neurological symptoms) before the 3-month injection is due. The biochemical argument is sound: serum B12 levels after injection peak at approximately 1 week and fall back to baseline-or-below by 4-8 weeks in many patients, because the excess B12 from the injection is excreted in urine within days — only the B12 that enters cells and is stored there contributes to long-term function. NICE guideline NG239 (2024) acknowledges that patients with neurological manifestations of PA should receive more frequent injections (every 2 months). For non-neurological PA where patients report early symptom recurrence, a trial of more frequent dosing (every 2 months) with reassessment is reasonable — there is no toxicity risk from more frequent hydroxocobalamin.

The folate-B12 interaction is one of the most important prescribing safety principles in haematology — giving folate alone to a patient with undiagnosed B12 deficiency causing megaloblastic anaemia will partially correct the macrocytic anaemia (because both B12 and folate are needed for the same DNA synthesis pathway, and supplementing one partially compensates for the deficiency of the other), but will not address the neurological B12 deficiency. The result: the macrocytic anaemia improves, the clinician believes the condition is treated, but neurological B12 deficiency progresses unchecked to SACD. This scenario is called 'subacute combined degeneration unmasked by folate treatment' and represents a clinical error. The safe practice: always check serum B12 and folate simultaneously in any patient with macrocytosis or unexplained neurological symptoms. If both are deficient: treat B12 first (or simultaneously with folate) — never treat folate alone without addressing B12 status. The NHS guidance on folic acid prescribing in primary care specifically states that serum B12 should be checked before folic acid supplementation in older patients.

The Pernicious Anaemia Society is the most important patient resource for PA management in the UK — it was founded in 2006 by Martyn Hooper after his own delayed PA diagnosis and provides: patient information leaflets, a helpline staffed by trained advisors, support groups across the UK, advocacy for improved diagnostic criteria (the society campaigns for testing functional B12 markers and broadening diagnostic criteria), and a travel card in multiple languages. The society has been instrumental in highlighting the problem of doctors discontinuing B12 injections after patients lose blood test abnormalities — once B12 injections normalise the MCV and the haemoglobin, some doctors query whether injections are still needed. They are — the underlying IF deficiency is permanent and will cause re-depletion within months of stopping. The society's leaflet 'What PA patients wish their GPs knew' is a valuable educational resource. GPs should provide the PA Society website (pernicious-anaemia-society.org) to every newly diagnosed PA patient.

The NICE NG239 (2024) guideline on B12 and folate deficiency provides updated guidance that significantly affects primary care practice — key updates include: (1) explicit recommendation for every-other-day IM hydroxocobalamin until neurological improvement for PA with neurological features (previously the duration was unclear); (2) recommendation for functional B12 testing (MMA and homocysteine) in borderline cases rather than empirical treatment or watchful waiting; (3) acknowledgement that some patients may require more frequent B12 injections based on individual clinical response; (4) specific guidance on oral versus IM treatment for different causes. GPs should be aware that the previous BCSH guideline on B12 deficiency (2014) has been superseded by NG239, which represents a significant update in diagnostic criteria and management recommendations. The key clinical message from NG239: treat based on clinical picture + serum B12 + functional markers where available; do not withhold treatment in symptomatic patients with borderline-low B12; ensure patients with neurological manifestations receive more frequent injections.